Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (71-80 of 193) with videos related to

Pageof 20
Sort By:
Oncotarget|September 6, 2018
Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemiaVeronica Martini, Federica Frezzato, Filippo Severin, et al.
Histopathology|June 20, 2017
Aberrant expression of CD10 and BCL6 in mantle cell lymphomaMarco Pizzi, Claudio Agostinelli, Simona Righi, et al.
Cancers|March 25, 2022
From Biology to Treatment of Monoclonal Gammopathies of Neurological SignificanceAndrea Visentin, Stefano Pravato, Francesca Castellani, et al.
Cancers|December 11, 2019
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow MicroenvironmentFilippo Severin, Federica Frezzato, Andrea Visentin, et al.
Annals of Hematology|April 23, 2016
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective studyPatrizia Mondello, Normann Steiner, Wolfgang Willenbacher, et al.
Journal of the Peripheral Nervous System : JPNS|May 29, 2023
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment responseLorenzo Bresciani, Alessandro Salvalaggio, Elisa Vegezzi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2016
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patientsAndrea Visentin, Silvia Imbergamo, Carmela Gurrieri, et al.
International Journal of Laboratory Hematology|March 12, 2026
Joint Assessment of CD38, CD138, and Immunoglobulin Light Chains Supports the Differential Diagnosis Between Classical Hodgkin Lymphoma and Plasmablastic LymphomaMarco Pizzi, Matteo Pischedda, Federico Scarmozzino, et al.
Oncotarget|January 5, 2018
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three casesAndrea Visentin, Silvia Imbergamo, Federica Frezzato, et al.
Biomarker Research|April 10, 2026
Outcomes of patients with CLL and borderline IGHV mutational status: a systematic review and meta analysisFrancesco Angotzi, Arianna Bevilacqua, Andrea Serafin, et al.
Pageof 20

Showing results (71-80 of 193) with videos related to

Sort By:
Pageof 20
Oncotarget|September 6, 2018
Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemiaVeronica Martini, Federica Frezzato, Filippo Severin, et al.
Histopathology|June 20, 2017
Aberrant expression of CD10 and BCL6 in mantle cell lymphomaMarco Pizzi, Claudio Agostinelli, Simona Righi, et al.
Cancers|March 25, 2022
From Biology to Treatment of Monoclonal Gammopathies of Neurological SignificanceAndrea Visentin, Stefano Pravato, Francesca Castellani, et al.
Cancers|December 11, 2019
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow MicroenvironmentFilippo Severin, Federica Frezzato, Andrea Visentin, et al.
Annals of Hematology|April 23, 2016
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective studyPatrizia Mondello, Normann Steiner, Wolfgang Willenbacher, et al.
Journal of the Peripheral Nervous System : JPNS|May 29, 2023
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment responseLorenzo Bresciani, Alessandro Salvalaggio, Elisa Vegezzi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2016
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patientsAndrea Visentin, Silvia Imbergamo, Carmela Gurrieri, et al.
International Journal of Laboratory Hematology|March 12, 2026
Joint Assessment of CD38, CD138, and Immunoglobulin Light Chains Supports the Differential Diagnosis Between Classical Hodgkin Lymphoma and Plasmablastic LymphomaMarco Pizzi, Matteo Pischedda, Federico Scarmozzino, et al.
Oncotarget|January 5, 2018
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three casesAndrea Visentin, Silvia Imbergamo, Federica Frezzato, et al.
Biomarker Research|April 10, 2026
Outcomes of patients with CLL and borderline IGHV mutational status: a systematic review and meta analysisFrancesco Angotzi, Arianna Bevilacqua, Andrea Serafin, et al.
Pageof 20